Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Ameriprise Financial Inc. grew its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 113.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,376 shares of the company's stock after acquiring an additional 36,928 shares during the period. Ameriprise Financial Inc. owned 0.07% of ARS Pharmaceuticals worth $732,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in SPRY. KLP Kapitalforvaltning AS acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $73,000. Compass Capital Corp MA ADV acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $106,000. Teacher Retirement System of Texas acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $122,000. Freestone Grove Partners LP acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $132,000. Finally, Amica Mutual Insurance Co. acquired a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $151,000. 68.16% of the stock is owned by institutional investors.

Insider Activity at ARS Pharmaceuticals

In other news, Director Laura Shawver sold 50,002 shares of the stock in a transaction on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,587,255.80. This represents a 19.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brent L. Saunders sold 120,000 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total transaction of $1,710,000.00. The disclosure for this sale can be found here. Insiders sold a total of 332,971 shares of company stock worth $4,621,888 in the last ninety days. 33.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

SPRY has been the subject of a number of analyst reports. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an "outperform" rating and a $40.00 price objective for the company. Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. William Blair restated an "outperform" rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Finally, Scotiabank began coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Trading Up 7.8%

NASDAQ:SPRY traded up $1.05 during trading hours on Friday, hitting $14.49. 1,273,223 shares of the company traded hands, compared to its average volume of 1,282,653. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -28.41 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The firm has a 50-day moving average of $13.97 and a 200 day moving average of $12.82.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million. Equities research analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.